Infusion, description

Pflanzen-asche, /. plant ashes, -aufguss, m plant infusion, -auszug, m, plant (or vegetable) extract, -base, /, vegetable base, (plant) alkaloid, -beachreibung, /, description of plants, phytography, -bestandteil,... 

A. General description Octreotide is a long-acting cyclic octapeptide (molecular weight 1.0 kDa) with pharmacologic actions mimicking those of the natural hormone somatostatin. The usefulness of natural somatostatin is limited by its extremely short duration of action, which requires continuous infusion. Octreotide is a molecular form (an octapeptide with two D-amino-acid substitutions) that overcomes the problem of short duration of action. 

Isidorus Hispalensis or Isidorus of Seville was a writer of the seventh century who wrote a work on the origin and signification of words. For such definition and descriptions as pertain to natural science he was dependent upon Greek and Latin authors with no infusion of Arabian science. Throughout the middle ages Isidorus was a much respected authority. A modern Latin text, edited by W. M. Lindsay, was published in Oxford in two octavo volumes in 1911. 

Rather than an in-depth technical description of the mechanics of extraction, this section presents briefly a typical infusion process, focusing on the factors that make extracts different from single-chemical components. Extracts by then nature are complex mixtures of (often) diverse active compounds contained within a plant matrix which are brought into solution by the extraction process. The aim of the extractor is to produce, over a period of time, batches of an extract meeting a customer s individual specification with as little variation as possible. There are parameters over which the extractor has some control, and these can be used to help achieve product consistency and also to fine-tune an extract to a particular customer s needs. 

Often, however, the information available is so indefinite that the search is hopeless from the beginning. The folklore that rheumatism can be cured by infusion of rheumatism root or rheumatism weed suggests the identification of this herb with a view to further investigation. Clute (3) has listed all such vernacular descriptive plant designations. Rheumatism root may be Chelone glabra (Scrophulariaceae), Chimaphila maculata (Ericaceae), Apocynum canna-binum (Apocynaceae), Jeffersonia diphylla (Berberidaoeae), or e en Dioscorea... 

Some of the publications consulted for this review offered insufficient description of use, lacking information about route of administration and the recipes concerning the medicines , as can be observed in Tables 1 and 2. In the cases in which they are described, recipes may include teas (infusion or decoction), bottled brews, or extract - in natura. While, route of administration may be ingestion and topical (in the form of bathing). 

The two-compartment model scheme is applied to the steady delivery of drug into the systemic circulation (zero-order absorption) in this section. The only difference between the instantaneous absorption and zero-order absorption two-compartment models is in the type of drug absorption. Thus all descriptions of what is included in each compartment, the use of micro and hybrid rate constants, and the different types of distribution volumes are identical to the two-compartment bolus IV model values. As was done previously for zero-order absorption, the model equations are written specifically for the case of IV infusion, with modifications for other types of zero-order absorption described in Section 10.11.5. 

The range of synthetic problems in this volume is also impressive including alkaloids, heterocycles, macrolides, terpenoids, polyketides, designed targets, sensors and many other systems that defy easy description. Infused in these analyses is the preeminent importance of step economy as it is becoming increasingly clear that the length of a synthesis influences if not determines most other economies and measures. This is clearly addressed by several contributors and perhaps... 

Clinical trials conducted during development (as described below in Sects. 12.2.6 and 12.2.7) were similar in a number of ways. Inclusion and exclusion criteria were almost identical across studies. These studies focused on the treatment of patients with relapsed or refractory LG/F NHL. Patients were dosed at 375 mg m of rit-uximab by intravenous infusion weekly for a total of four doses. This consistency resulted in a degree of homogeneity that allowed for analyses across studies as well as comparisons between studies. Any exceptions to these general rules are noted in the individual study descriptions below. 

---